We want to give a new lease of life to chronic pain patients all over the world. With the development of VER-01, we have reached our first significant milestone.
Vertanical is a globally leading biopharmaceutical company that specializes in the development and distribution of innovative medicinal products for the treatment of chronic pain. Everything we do is guided by one clear vision: A world free of chronic pain!
We have now developed VER-01, a unique cannabinoid-based medicinal product for the treatment of chronic pain, which represents a first key milestone after more than eight years of intensive research and development work.
Our goal was to develop a pain medication that goes beyond the purely analgesic (pain-relieving) effect of conventional painkillers, also offering significant relief from symptoms that typically accompany chronic pain, such as sleep disorders and depressive moods.
Building on our successes in clinical development, we are pursuing the ambitious mission of establishing VER-01 as a leading therapy for the treatment of chronic pain by 2030, and in the process setting new standards in pain management.
A world free of chronic pain
OUR VISION
Despite the treatments currently available, millions of patients are suffering considerable pain
Over a billion people worldwide suffer from chronic pain, often accompanied by sleep problems and depression. While acute pain has an important protective function, chronic pain serves no physiological purpose.
Neuroscientific studies have shown that in cases of chronic pain the brain reacts hyper sensitively, transmitting pain signals even when no actual pain stimulus is present.
What’s more, with the medications currently available – particularly opioids – many patients achieve only inadequate pain relief and often see no improvement in their sleep problems or depressive symptoms. Many chronic pain patients additionally suffer substantial side effects from the treatment they have received so far.
So despite the treatment options available today, chronic pain continues to be a constant companion for over 400 million people worldwide, severely impacting their quality of life.
Our mission is to establish VER-01 as the leading therapy for the treatment of chronic pain by 2030
OUR MISSION
Innovation leadership in the treatment of chronic pain
We believe that research and development is the impetus which powers groundbreaking innovation. In our mission to improve life for chronic pain patients all over the world, we are already investing tens of millions into research and development every year.
Our work here relies on a specialized team which performs our clinical trials, as well as an international network of several hundred research and trial centers throughout Europe and the USA.
We also operate one of the world’s most advanced sites for the development and production of biologic medications in line with the highest GMP standards.
With an extensive development program examining the efficacy and safety of VER-01 in more than 20 pre-clinical and clinical trials, Vertanical is already one of the leading innovators in the treatment of chronic pain. We reached an important milestone in July 2024, when we submitted our application for the approval of VER-01 as a finished medicinal product for the treatment of chronic lower back pain.
Our development pipeline
Development name
VER-01
Indication
Chronic non-specific low back pain
Objective
Evaluation of pharmacokinetics and safety in healthy volunteers
Complete
Phase 1
Development name
VER-01
Indication
Chronic low back pain
Objective
Efficacy, safety and sustained efficacy compared to placebo
Complete
Phase 3
Development name
VER-01
Indication
Chronic low back pain
Objective
Tolerability, efficacy and safety compared to opioids
Complete
Phase 3
Development name
VER-01
Indication
Chronic low back pain
Objective
Dose-response relationship
Ongoing
Phase 2
Development name
VER-01
Indication
Chronic low back pain
Objective
Efficacy and safety compared to placebo
Preparation
Phase 3
Development name
VER-01
Indication
Osteoarthritis
Objective
Efficacy, safety and sustained efficacy compared to placebo
Planned for 2025
Phase 3
Development name
VER-01
Indication
Osteoarthritis
Objective
Tolerability, efficacy and safety compared to opioids
We are working together for a world free of chronic pain, and we firmly believe that such a world can only be achieved with perseverance and the courage to chart new territory. These guiding principles are applied not only when recruiting new talent, but also in the composition of our management team.
Our clearly defined values form the foundation for everything we do and are the key to our success. We are confident that small, dynamic and high-performing teams of excellent employees have the potential to transform chronic pain treatment in the long term.
We believe in the power of small A‑teams
We are convinced that a small team of A-Players can achieve EVERYTHING!
We embrace persistence
We believe persistence drives achievement. We reject "No" as an answer.
We continuously improve ourselves
We consistently question ourselves and challenge our views with believable persons.
We strive for excellence
We dedicate ourselves to excellence in all aspects of our business and people.
We embrace full transparency
We speak up and voice our opinions clearly.
We keep it safe
We stay away from anything illegal, dishonest, or immoral.
News
04.12.2024
Regulatory authorities grant VERTANICAL the manufacturing authorization for finished pharmaceutical products
18.10.2024
VERTANICAL at the German Pain Conference in Mannheim
18.10.2024
Last patient visit for Phase 3 comparative study on opioids treatment
Do you want to actively contribute to the introduction of VER-01 as a leading treatment for chronic pain patients, and offer millions of people a new perspective on a life without chronic pain?
Then why not visit our Careers page and apply for one of our many exciting positions?
Clemens founded FUTRUE-Group in 2007 and has been its CEO ever since. He discovered his passion for enterprise at the early age of 17, when he set up his own cell phone company. Since then, the serial entrepreneur has founded numerous healthcare companies with FUTRUE, some of which have been successfully placed on the market and then sold to pharmaceutical giants such as Novartis, Dermapharm and Perrigo. By funding Vertanical, he is pursuing the vision of a world free of chronic pain. Before he set up FUTRUE Clemens worked for several companies, including Novartis, where he was responsible for the Strategy and Cardiovascular divisions as a member of the German executive board.
Clemens holds a Master’s degree from Harvard University, in Business Economics and Business Administration, as well as a license to practice medicine and a doctorate in medicine from the Technical University of Munich.
Bastian is the CEO of VERTANICAL. He is responsible for the Clinical, Non-Clinical and Pharmaceutical Development divisions, including areas such as Regulatory Affairs and Quality Assurance. His primary focus lies on strategic development and the completion of clinical trials and approval processes. Bastian began his career with the FUTRUE-Group as a research associate in 2014 and then progressed further within the Group, serving in several leadership roles. He has been CEO since 2018.
Bastian has a Master’s degree in Ecotrophology from the Christian-Albrechts University of Kiel.
As Chief Commercial Officer, Sebastian is responsible for Sales, Marketing, and Production divisions at VERTANICAL. A key focus of his role is building the commercial structures for the market launch of VER-01 in Germany and internationally. Before joining VERTANICAL, Sebastian spent six years as an Associate Partner at McKinsey & Company, specializing in marketing and sales topics. Prior to that, he gained several years of experience in the banking and private equity sectors in Frankfurt and Cologne.
Sebastian studied Economics and Finance in Frankfurt, Melbourne and Cape Town.
DE
EN
DE
EN
